期刊
HPB
卷 12, 期 5, 页码 313-320出版社
ELSEVIER SCI LTD
DOI: 10.1111/j.1477-2574.2010.00183.x
关键词
consensus conference; hepatocellular cancer; hepatoma; surgery; chemotherapy; radiotherapy; chemoembolization; liver transplantation
资金
- American Hepato-Pancreato Biliary Association
- Society of Surgical Oncology
- Society for Surgery of the Alimentary Tract
- University of Texas M. D. Anderson Cancer Center in Orlando, FL
Although surgical resection and liver transplantation are the only treatment modalities that enable prolonged survival in patients with hepatocellular carcinoma (HCC), the majority of HCC patients presents with advanced disease and do not undergo resective or ablative therapy. Transarterial chemoembolization (TACE) is indicated in intermediate/advanced stage unresectable HCC even in the setting of portal vein involvement (excluding main portal vein). Sorafenib has been shown to improve survival of patients with advanced HCC in two controlled randomized trials. Yttrium 90 is a safe microembolization treatment that can be used as an alternative to TACE in patients with advanced liver only disease or in case of portal vein thrombosis. External beam radiation can be helpful to provide local control in selected unresectable HCC. These different treatment modalities may be combined in the treatment strategy of HCC and also used as a bridge to resection or liver transplantation. Patients should undergo formal multidisciplinary evaluation prior to initiating any such treatment in order to individualize the best available options.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据